Home › Therapeutic areas › Oncology

Oncology (108 companies · 53 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Oncology Lead stage Mkt cap Programs
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 8 Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology 3 Phase 2 $15.2M 4
ADAG Adagene Oncology 6 Phase 2 $99.4M 10
ADCT ADC Therapeutics Oncology 5 Approved $172M 5
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
AKTS Aktis Oncology Oncology 8 Phase 1 $910M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 1 NDA Submitted $41.9M 5
ALLO Allogene Therapeutics ImmunologyOncology Rare 7 Phase 2 $256M 10
DRTS Alpha Tau Medical Oncology 6 Phase 2 $1.12B 6
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 1 Phase 2 $161M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 2 Approved $1.36B 9
ANIX Anixa Biosciences Oncology 3 Phase 1 $92.8M 3
APVO Aptevo Therapeutics Oncology 5 Phase 1 $1.6M 8
RCUS Arcus Biosciences DermatologyImmunology+1 4 Phase 3 $2.36B 8
AVBP ArriVent BioPharma Oncology 7 Phase 3 $553M 7
ARTV Artiva Biotherapeutics Oncology 5 Phase 1 $191M 6
ARVN Arvinas NeurologyOncology Rare 6 Approved $447M 10
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 8 Approved $290M 12
BCAX Bicara Therapeutics Oncology 4 Phase 2 $637M 4
BCYC Bicycle Therapeutics Oncology 3 Phase 2 $224M 4
BMEA Biomea Fusion MetabolicOncology 1 Phase 2 $35.5M 4
BDTX Black Diamond Therapeutics Oncology 3 Phase 2 $82.8M 4
BCTX BriaCell Therapeutics Oncology 7 Phase 3 $30.7M 8
BBOT BridgeBio Oncology Therapeutics Oncology 6 Phase 1 $156M 6
CCCC C4 Therapeutics Oncology 2 Phase 2 $332M 2
CADL Candel Therapeutics Oncology 3 Phase 3 $424M 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $187M 4
CLRB Cellectar Biosciences Oncology 7 Phase 2 $9.2M 7
CGON CG Oncology Oncology 1 NDA Submitted $7.05B 1
COGT Cogent Biosciences HematologyOncology Rare 3 NDA Submitted $4.85B 7
CHRS Coherus Oncology Oncology 5 Approved $74.0M 5
CMPX Compass Therapeutics Oncology 12 Phase 2 $109M 15
CGEN Compugen Oncology 7 Phase 3 $191M 7
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 2 Phase 3 $858M 7
CBIO Crescent Biopharma Oncology 9 Phase 2 $507M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved — 6
CUE Cue Biopharma ImmunologyOncology 1 Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 3 NDA Submitted $602M 10
CYDY CytoDyn NeurologyOncology 2 Phase 2 $367M 3
CTMX CytomX Therapeutics Oncology 6 Phase 1 $423M 7
IRON Disc Medicine GI/HepatologyHematology+2 Rare 1 Phase 3 $3.49B 9
EIKN Eikon Therapeutics Oncology 12 Phase 2 $279M 13
ELTX Elicio Therapeutics Oncology 4 Phase 2 $40.5M 6
ELVN Enliven Therapeutics Oncology 1 Phase 1 $3.45B 1
ERAS Erasca Oncology 4 Phase 1 $4.87B 5
EXEL Exelixis CardiovascularOncology 17 Approved $16.7B 23
FATE Fate Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $124M 10
FHTX Foghorn Therapeutics Oncology 3 Preclinical $110M 4
FBIO Fortress Biotech DermatologyHematology+4 Rare 5 Approved $61.4M 16
GNLX Genelux Oncology 3 Phase 3 $96.1M 3
GERN Geron Oncology 3 Approved $644M 3
GLSI Greenwich LifeSciences Oncology 1 Phase 3 $274M 1
IDYA IDEAYA Biosciences Oncology 9 NDA Submitted $2.65B 15
IMTX Immatics Oncology 7 Phase 3 $958M 8
IMRX Immuneering Oncology 4 Phase 3 $224M 5
IBRX ImmunityBio Infectious DiseaseOncology 13 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 7 Approved $1.44B 12
IMNM Immunome Oncology Rare 9 NDA Submitted $2.03B 9
INAB IN8bio ImmunologyOncology 3 Phase 1 $8.9M 4
INBX Inhibrx Biosciences Oncology 5 NDA Submitted $1.10B 6
JANX Janux Therapeutics Oncology 3 Phase 1 $655M 4
KAPA Kairos Pharma Oncology 9 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 10 Phase 2 $60.7M 13
KROS Keros Therapeutics NeurologyOncology Rare 2 Phase 3 $222M 5
KURA Kura Oncology MetabolicOncology 9 Approved $688M 13
LEGN Legend Biotech Oncology Rare 15 Approved $3.12B 17
MAIA MAIA Biotechnology Oncology 5 Phase 3 $77.2M 8
MRKR Marker Therapeutics Oncology 5 Phase 1 $14.0M 5
MDNAF Medicenna Therapeutics Oncology 3 Phase 2 $14.8M 10
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 4 Phase 2 $47.7M 8
MBRX Moleculin Biotech Oncology 6 Phase 2 $7.3M 9
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 2 Phase 2 $775M 7
NKTR Nektar Therapeutics DermatologyImmunology+2 3 Phase 3 $1.23B 11
NBP NovaBridge Biosciences OncologyOphthalmology 5 Phase 2 $95.4M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 9 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 6 Phase 3 $660M 9
OLMA Olema Pharmaceuticals Oncology 3 Phase 3 $633M 3
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.04B 6
ONCY Oncolytics Biotech Oncology 3 Phase 2 $51.7M 4
OKUR OnKure Therapeutics Oncology 1 Preclinical $104M 2
ORIC Oric Pharmaceuticals Oncology 4 Phase 3 $831M 5
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 $16.0M 4
CATX Perspective Therapeutics Oncology 4 Phase 1 $104M 5
PHIO Phio Pharmaceuticals Oncology 3 Phase 1 $8.6M 4
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 $92.2M 7
PYPD PolyPid Infectious DiseaseMetabolic+1 1 NDA Submitted $138M 4
PRLD Prelude Therapeutics HematologyOncology Rare 2 Phase 1 $266M 3
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $143M 3
RXRX Recursion Pharmaceuticals Oncology 4 Phase 2 $1.69B 6
RLAY Relay Therapeutics DermatologyOncology Rare 3 Approved $3.64B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $321M 4
REPL Replimune Group Oncology 5 Approved $1.87B 5
RVMD Revolution Medicines Oncology 7 Approved $35.2B 11
SANA Sana Biotechnology MetabolicOncology 2 Phase 1 $563M 4
SLS SELLAS Life Sciences Group Oncology 8 Phase 3 $3.90B 9
SMMT Summit Therapeutics Oncology 6 NDA Submitted $8.53B 6
STRO Sutro Biopharma Oncology 3 Phase 1 $148M 3
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 6 Approved $822M 7
TNGX Tango Therapeutics Oncology 5 Phase 1 $3.75B 5
TLX Telix Pharmaceuticals Oncology 20 Approved $3.01B 25
HURA TuHURA Biosciences Oncology 4 Phase 3 $92.1M 4
TYRA Tyra Biosciences MetabolicOncology Rare 4 Phase 2 $1.35B 5
VSTM Verastem Oncology 5 Approved $934M 5
VRCA Verrica Pharmaceuticals DermatologyOncology Rare 1 Approved $53.9M 4
VIR Vir Biotechnology Infectious DiseaseOncology Rare 3 Phase 3 $1.58B 6
XNCR Xencor ImmunologyNeurology+1 Rare 16 Approved $2.59B 28
ZNTL Zentalis Pharmaceuticals Oncology 1 Phase 3 $146M 1
ZYME Zymeworks OncologyRespiratory 10 Approved $1.78B 12